Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $50.11.

A number of research analysts have commented on the company. The Goldman Sachs Group decreased their price target on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. UBS Group decreased their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Celldex Therapeutics in a research note on Friday, June 13th. Morgan Stanley decreased their price target on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Finally, Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a “buy” rating and a $64.00 price target on the stock.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $22.85 on Wednesday. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -8.46 and a beta of 1.13. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock has a 50 day moving average of $20.64 and a 200 day moving average of $21.05.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Analysts forecast that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Several hedge funds have recently modified their holdings of CLDX. EverSource Wealth Advisors LLC increased its holdings in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 878 shares during the last quarter. GAMMA Investing LLC increased its holdings in Celldex Therapeutics by 6,665.9% in the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 2,933 shares during the last quarter. Headlands Technologies LLC purchased a new position in Celldex Therapeutics in the fourth quarter valued at $81,000. AlphaQuest LLC increased its holdings in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Celldex Therapeutics in the fourth quarter valued at $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.